Back to News
Market Impact: 0.4
Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
Source: businesswire.com
Healthcare & Biotech
Izalontamab brengitecan (Iza-Bren) reduced the risk of disease progression or death by 59% versus chemotherapy in patients with advanced HR+/HER2- disease, according to the headline. The excerpt provides no additional trial details or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.60
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
- Cumberland Pharmaceuticals stock tumbles on trial results